XML 63 R49.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Research and License Agreements - Additional Information (Detail) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2015 USD ($) | May 31, 2014 USD ($) | Dec. 31, 2018 USD ($) item | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Research and License Agreements |  |  |  |  |
Revenue | $ 20,000,000 | $ 15,000,000 |  |  | $ 18,500
License Agreement | Pfizer |  |  |  |  |
Research and License Agreements |  |  |  |  |
Up-front payment received |  |  | $ 22,500,000 |  |
Transaction price |  |  | 22,500,000 |  |
Non-cash consideration received |  |  | $ 0 |  |
Research Services Agreement | University Of Basel |  |  |  |  |
Research and License Agreements |  |  |  |  |
Royalty payment due against license fees received (as a percent) |  |  | 10.00% |  |
Consideration paid |  |  | $ 0 | $ 0 | $ 0
Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum |  |  |  |  |
Research and License Agreements |  |  |  |  |
Potential milestone payments |  |  | 115,000,000 |  |
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum |  |  |  |  |
Research and License Agreements |  |  |  |  |
Potential milestone payments |  |  | 70,000,000 |  |
Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum |  |  |  |  |
Research and License Agreements |  |  |  |  |
Potential milestone payments |  |  | $ 135,000,000 |  |
Achievement Of First Commercial Sale Of Licensed Product | License Agreement | Pfizer |  |  |  |  |
Research and License Agreements |  |  |  |  |
Number of indications | item |  |  | 2 |  |
Achievement Of Dosing First Patient In Clinical Trial | License Agreement | Pfizer |  |  |  |  |
Research and License Agreements |  |  |  |  |
Non-refundable milestone payment received | $ 20,000,000 | $ 15,000,000 |  |  |
Achievement Of Dosing First Patient In Clinical Trial | License Agreement | Pfizer | Maximum |  |  |  |  |
Research and License Agreements |  |  |  |  |
Number of indications | item |  |  | 2 |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | glyc_ArrangementsAndNonarrangementTransactionsLineItems
Namespace Prefix: | glyc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration paid to counterparty as part of the arrangement in the evaluation of the agreement under ASC 606. + References No definition available. + Details
Name: | glyc_ConsiderationPaid
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of non-cash consideration received in the evaluation of the agreement under ASC 606. + References No definition available. + Details
Name: | glyc_NonCashConsiderationReceived
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of non-refundable milestone payment received. + References No definition available. + Details
Name: | glyc_NonrefundableMilestonePaymentReceived
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of indications that trigger payment of milestones under the agreement. + References No definition available. + Details
Name: | glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement
Namespace Prefix: | glyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the potential payment that may be received upon achievement of specified milestones per agreement. + References No definition available. + Details
Name: | glyc_PotentialPaymentForAchievementOfSpecifiedMilestones
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the royalty commitment due as a percent of the milestone payments received under licensing arrangement. + References No definition available. + Details
Name: | glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent
Namespace Prefix: | glyc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration determined to be the transaction price under the agreement recognized under ASC 606. + References No definition available. + Details
Name: | glyc_TransactionPrice
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of up-front payment received under terms of the agreement. + References No definition available. + Details
Name: | glyc_UpFrontPaymentReceived
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=glyc_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glyc_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=glyc_UniversityOfBaselMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfFirstCommercialSaleOfLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfDosingFirstPatientInClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |